ID   NK-92 GFP
AC   CVCL_VN56
SY   GFP+NK-92.05; GFP aNK control
DR   Wikidata; Q98127905
WW   Provider; Brink Biologics; -; https://brinkbiologics.com/platform/
CC   Population: Caucasian.
CC   Genetic integration: Method=Transfection/transduction; Gene=FPbase; R9NL8; eGFP (Note=Enhanced GFP).
CC   Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers for this cell line. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Natural killer cell; CL=CL_0000623.
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2142 ! NK-92
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 10-04-25; Version: 8
//